Immune Surveillance and Effector Functions of CCR10+ Skin Homing T Cells

Hudak, Susan; Hagen, Michael; Liu, Ying; Catron, Daniel; Oldham, Elizabeth R.; McEvoy, Leslie M.; Bowman, Edward P.

doi:10.4049/jimmunol.169.3.1189

Cited by 108 publications

(101 citation statements)

References 53 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47 CCR10 (receptor for CCL27) is known as a chemokine receptor that is preferentially expressed among blood leukocytes by a subset of memory CD4 þ and CD8 þ T cells, and CCR10-positive T cells that coexpress the skin-homing receptor, cutaneous lymphocyte antigen, can act as both 'central' and 'effector' memory T cells. 48 These previous results supported our data that intratumoral injection of AdRGD-CCL17, -CCL22, or -CCL27, but not AdRGD-CCL19, was effective for promoting the anti-B16BL6 tumor efficacy and the infiltration of immune effector cells in mice immunized with gp100/DCs. Therefore, the selection of chemokine in cancer immunogenetherapy must consider the host's immune activation status and characteristics of other combined therapies on immunomodulation.…”

Section: Discussionsupporting

confidence: 89%

Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector

et al. 2005

View full text Add to dashboard Cite

Our goal in the present study was to evaluate antitumor effects and frequency of tumor-infiltrating immune cells upon intratumoral injection of RGD fiber-mutant adenoviral vector (AdRGD) encoding the chemokines CCL17, CCL19, CCL20, CCL21, CCL22, CCL27, XCL1, and CX3CL1. Among eight kinds of chemokine-expressing AdRGDs, AdRGD-CCL19 injection most efficiently induced infiltration of T cells into established B16BL6 tumor parenchyma, whereas most of these T cells were perforin-negative in immunohistochemical analysis. Additionally, the growth of AdRGD-CCL19-injected tumors decreased only slightly as well as that of other tumors treated with each chemokine-expressing AdRGD, which indicated that accumulation of naive T cells in tumor tissue does not effectively damage the tumor cells. Tumor-bearing mice, in which B16BL6-specific T cells were elicited by dendritic cellbased immunization, demonstrated that intratumoral injection of AdRGD-CCL17, -CCL22, or -CCL27 could considerably suppress tumor growth and attract activated T cells. On the other hand, AdRGD-CCL19-injection in the immunized mice showed slight increase of tumor-infiltrating T cells compared to treatment using control vector. Collectively, although AdRGD-mediated chemokine gene transduction into established tumors would be very useful for augmentation of tumor-infiltrating immune cells, a combinational treatment that can systemically induce tumor-specific effector T cells is necessary for satisfactory antitumor efficacy.

show abstract

Section: Discussionsupporting

confidence: 89%

Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector

et al. 2005

View full text Add to dashboard Cite

show abstract

“…25 We sought to determine if CCR10 and other chemokine receptors are expressed by CTCL. Our findings confirm reports of a potential role of CXCR3 in MF and, by applying the WHO criteria for diagnostics, expand these findings to SS as well as other forms of CTCL.…”

Section: Discussionmentioning

confidence: 99%

CCR10 is expressed in cutaneous T‐cell lymphoma

Notohamiprodjo

Segerer

Huss

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma (CTCL) is characterized by recruitment of malignant T-cell clones into the skin. The mechanisms involved in tumor homing are still not fully elucidated, though chemokines and chemokine receptors have been suggested to play a role in the pathogenesis. Here, we demonstrate extensive expression of CCR10 in skin biopsies of patients with Sézary syndrome (SS, n = 3), mycosis fungoides (MF, n = 2) and unspecified CTCL (n = 3). In addition, we expand prior findings of CXCR3 expression in MF to other entities of CTCL. Expression of CCR5 was detected in 2 of the examined skin biopsies. The functionality of CCR10 and CXCR3 in SS was demonstrated using the SS T-cell line HUT78. Our data support a potential role of CXCR3 in CTCL and strongly suggest that CCR10 and its ligand CCL27 may contribute to the skin infiltration of malignant T-cells in this group of lymphoproliferative disorders. ' 2005 Wiley-Liss, Inc.

show abstract

“…Accordingly, CCR10 has been shown to be expressed by skinhoming effector/memory T cells expressing cutaneous lymphocyte Ag (14,17,18). Subsequently, another ligand of CCR10 was identified and termed CCL28, which is widely expressed by the epithelial cells of various mucosal tissues (11, 19 -21).…”

Section: 25-dihydroxyvitamin D 3 Induces Ccr10 Expression In Terminmentioning

confidence: 99%

1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells

Shirakawa

Nagakubo

Hieshima

et al. 2008

The Journal of Immunology

View full text Add to dashboard Cite

In the B cell lineage, CCR10 is known to be selectively expressed by plasma cells, especially those secreting IgA. In this study, we examined the regulation of CCR10 expression in terminally differentiating human B cells. As reported previously, IL-21 efficiently induced the differentiation of activated human CD19+ B cells into IgD−CD38+ plasma cells in vitro. A minor proportion of the resulting CD19+IgD−CD38+ cells expressed CCR10 at low levels. 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), the active metabolite of vitamine D3, dramatically increased the proportion of CD19+IgD−CD38+ cells expressing high levels of CCR10. The 1,25-(OH)2D3 also increased the number of CCR10+ cells expressing surface IgA, although the majority of CCR10+ cells remained negative for surface IgA. Thus, 1,25-(OH)2D3 alone may not be sufficient for the induction of IgA expression in terminally differentiating human B cells. To further determine whether 1,25-(OH)2D3 directly induces CCR10 expression in terminally differentiating B cells, we next performed the analysis on the human CCR10 promoter. We identified a proximal Ets-1 site and an upstream potential vitamin D response element to be critical for the inducible expression of CCR10 by 1,25-(OH)2D3. We confirmed the specific binding of Ets-1 and 1,25-(OH)2D3-activated vitamin D receptor to the respective sites. In conclusion, 1,25-(OH)2D3 efficiently induces CCR10 expression in terminally differentiating human B cells in vitro. Furthermore, the human CCR10 promoter is cooperatively activated by Ets-1 and vitamin D receptor in the presence of 1,25-(OH)2D3.

show abstract

Immune Surveillance and Effector Functions of CCR10+ Skin Homing T Cells

Cited by 108 publications

References 53 publications

Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector

Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector

CCR10 is expressed in cutaneous T‐cell lymphoma

1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells

Contact Info

Product

Resources

About